Venus Remedies Ltd (VENUSREM) is currently trading at 1,310.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Venus Remedies Ltd is a pharmaceutical company specializing in injectables and intravenous supplies with global reach through WHO-GMP certified facilities. In recent years, the company has had notable product launches, including the innovative anti-cancer drug 'Docetaxel' in Europe and 'Cytomib,' a treatment for blood cancer. Venus Remedies has been expanding its consumer healthcare product line, notably launching R3SET, a pain management solution, in 2021-22. The company has focused on process automation and business intelligence, adopting systems such as retail billing automation and implementing a BI tool like Tableau for decision-making. Recent advancements in their R&D efforts include the launch of ELORES, an antibiotic that tackles superbugs, significantly strengthening its product portfolio.

Over the past 52 weeks, Venus Remedies Ltd has traded between a low of ₹439.10 and a high of ₹2,043.15. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Venus Remedies Ltd has a market capitalization of approximately 1,763.11. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Venus Remedies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 14.49 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,763.11 Cr, Venus Remedies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Venus Remedies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Venus Remedies Ltd is 14.49. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Venus Remedies received marketing authorisation from the Saudi Food and Drug Authority (SFDA) for Plerixafor, a speciality oncology therapy.